Publications in collaboration with researchers from Hospital Universitario Son Espases (22)

2024

  1. Impact of chromosomally encoded resistance mechanisms and transferable β-lactamases on the activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa

    Journal of Antimicrobial Chemotherapy, Vol. 79, Núm. 10, pp. 2591-2597

  2. Impact of transferable β-lactamases and intrinsic AmpC amino acid substitutions on the activity of cefiderocol against wild-type and iron uptake-deficient mutants of Pseudomonas aeruginosa

    The Journal of antimicrobial chemotherapy, Vol. 79, Núm. 11, pp. 3023-3028

2023

  1. Simultaneous and divergent evolution of resistance to cephalosporin/β-lactamase inhibitor combinations and imipenem/relebactam following ceftazidime/avibactam treatment of MDR Pseudomonas aeruginosa infections

    The Journal of antimicrobial chemotherapy, Vol. 78, Núm. 5, pp. 1195-1200

2022

  1. Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa

    The Journal of antimicrobial chemotherapy, Vol. 77, Núm. 10, pp. 2809-2815

  2. Selection of AmpC β-Lactamase Variants and Metalloβ- Lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/ XDR Pseudomonas aeruginosa Infections

    Antimicrobial Agents and Chemotherapy, Vol. 66, Núm. 2

2021

  1. 6-Halopyridylmethylidene Penicillin-Based Sulfones Efficiently Inactivate the Natural Resistance of Pseudomonas aeruginosa to β-Lactam Antibiotics

    Journal of Medicinal Chemistry, Vol. 64, Núm. 9, pp. 6310-6328

  2. Molecular mechanisms driving the in vivo development of OXA-10-mediated resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of XDR Pseudomonas aeruginosa infections

    The Journal of antimicrobial chemotherapy, Vol. 76, Núm. 1, pp. 91-100

2020

  1. Molecular and biochemical insights into the in vivo evolution of AmpC-mediated resistance to ceftolozane/tazobactam during treatment of an MDR Pseudomonas aeruginosa infection

    The Journal of antimicrobial chemotherapy, Vol. 75, Núm. 11, pp. 3209-3217

2019

  1. Challenging antimicrobial susceptibility and evolution of resistance (oxa-681) during treatment of a long-term nosocomial infection caused by a pseudomonas aeruginosa ST175 Clone

    Antimicrobial Agents and Chemotherapy, Vol. 63, Núm. 10

  2. Therapeutic Efficacy of LN-1-255 in Combination with Imipenem in Severe Infection Caused by Carbapenem-Resistant Acinetobacter baumannii

    Antimicrobial Agents and Chemotherapy, Vol. 63, Núm. 10

2018

  1. Increased Antimicrobial Resistance in a Novel CMY-54 AmpC-Type Enzyme with a GluLeu217-218 Insertion in the Ω-Loop

    Microbial Drug Resistance, Vol. 24, Núm. 5, pp. 527-533

2014

  1. Genetic and kinetic characterization of the novel AmpC β-lactamases DHA-6 and DHA-7

    Antimicrobial Agents and Chemotherapy, Vol. 58, Núm. 11, pp. 6544-6549

2012

  1. Characterization of a novel IMP-28 metallo-β-lactamase from a Spanish Klebsiella oxytoca clinical isolate

    Antimicrobial Agents and Chemotherapy, Vol. 56, Núm. 8, pp. 4540-4543

  2. Pan-β-lactam resistance development in Pseudomonas aeruginosa clinical strains: Molecular mechanisms, penicillin-binding protein profiles, and binding affinities

    Antimicrobial Agents and Chemotherapy, Vol. 56, Núm. 9, pp. 4771-4778

2011

  1. False extended-spectrum β-lactamase phenotype in clinical isolates of escherichia coli associated with increased expression of OXA-1 or TEM-1 penicillinases and loss of porins

    Journal of Antimicrobial Chemotherapy, Vol. 66, Núm. 9, pp. 2006-2010

  2. Phosphoethanolamine modification of lipid A in colistin-resistant variants of Acinetobacter baumannii mediated by the pmrAB two-component regulatory system

    Antimicrobial Agents and Chemotherapy, Vol. 55, Núm. 7, pp. 3370-3379

  3. Role of changes in the L3 loop of the active site in the evolution of enzymatic activity of VIM-type metallo-β-lactamases-authors' response

    Journal of Antimicrobial Chemotherapy

2010

  1. Clinical features of infections and colonization by Acinetobacter genospecies 3

    Journal of Clinical Microbiology, Vol. 48, Núm. 12, pp. 4623-4626

  2. Role of changes in the L3 loop of the active site in the evolution of enzymatic activity of VIM-type metallo-β-lactamases

    Journal of Antimicrobial Chemotherapy, Vol. 65, Núm. 9, pp. 1950-1954

2008

  1. Characterization of the new metallo-β-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain

    Antimicrobial Agents and Chemotherapy, Vol. 52, Núm. 10, pp. 3589-3596